Abstract:4613 Background: In the phase 3 study (SANET-ep, NCT02588170), surufatinib significantly prolonged progression free survival compared with placebo in patients with progressive, well-differentiated advanced extrapancreatic neuroendocrine tumors (epNETs) (ESMO 2019 Abs. LBA76). Here, we report the results of health-related quality-of-life (HRQoL) from this study. Methods: Eligible patients were randomized in a 2:1 ratio to receive surufatinib or placebo, 300 mg, orally, once daily, until disease progression or intolerable adverse events. Patient-reported outcome questionnaires, including the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the QLQ-G.I.NET-21, were collected at baseline, Day 15 of the first cycle (28 Days/cycle), and Day 1 of every cycle thereafter and at discontinuation. Time until definitive deterioration (TUDD) was defined as time from randomization to deterioration of 10 points in domain score compared with baseline score (without subsequent observations of deterioration of less than 10 point or any improvement as compared to baseline score), or death due to any cause. TUDD and mean change from baseline based on a longitudinal repeated measures analysis of each domain were analyzed retrospectively. Significance testing was at two-sided 0.05 without adjustment for multiplicity. Results: Of 198 pts randomized (surufatinib n = 129; placebo n = 69), 197 (99.5%) patients completed HRQoL questionnaires at baseline. The questionnaire compliance rate was >90% for most on-treatment assessments. The TUDD was significantly longer in the surufatinib arm versus the placebo arm in the dyspnea domain (hazard ratio [HR] 0.52, p = 0.0103) and social function scale (HR 0.58, p = 0.0222), while the TUDD of diarrhea was significantly shorter in the surufatinib arm compared to placebo (HR 2.68, p = 0.0074). There was no significant difference of TUDD in the remaining domains of QLQ-C30 and G.I.NET-21. There was also no significant difference of the mean change of scores from baseline by repeated measures in the domains between the two arms except diarrhea (increase of 14.0 points [95% CI 9.6, 18.4] in the surufatinib arm versus 2.1 points [95% CI -4.1, 8.4] in the placebo arm, p = 0.0007). Conclusions: Treatment with surufatinib resulted in superior efficacy, acceptable toxicity, while generally maintaining HRQoL, which support surufatinib as a treatment option in this patient population that was previously treated with available therapies for epNETs. Clinical trial information: NCT02588170 .

Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors

Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data

The Efficacy and Safety of Sunitinib in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors.

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

Clinical Efficacy and Safety of Sunitinib After Imatinib Failure in Japanese Patients with Gastrointestinal Stromal Tumor

Efficacy and Safety of Sunitinib in Chinese Patients with Imatinib-Resistant or -Intolerant Gastrointestinal Stromal Tumors.

The Evaluation of Efficacy and Safety of Sunitinib on EGFR‐TKI Pretreated Advanced Non‐small Cell Lung Cancer Patients in China

Sunitinib is Effective and Tolerable in Chinese Patients with Advanced Pancreatic Neuroendocrine Tumors: a Multicenter Retrospective Study in China

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

Clinical Efficacy and Tolerance of Sunitinib in the Treatment of Advanced Renal Cell Carcinoma

[Exploratory Analysis of the Effect of Toxicity of Sunitinib on the Clinical Outcome of Patients with Advanced Renal Cell Carcinoma].

Evaluation of Efficacy and Safety of Sunitinib Regimen in 22 Patients with Metastatic Renal Cell Carcinoma: at Least 12-Month Follow-Up.

Efficacy of sunitinib in patients with metastatic renal cell carcinoma: initial experience in two Chinese centers.

Efficacy and safety of streptozocin-based chemotherapy for gastroenteropancreatic neuroendocrine tumors in Japanese clinical practice

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

Health-related Quality-of-life Results from SANET-ep: A Phase III Study of Surufatinib Versus Placebo for Advanced Extrapancreatic Neuroendocrine Tumors.

Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)

Hematological Adverse Events of Sunitinib in Treatment of Advanced Renal Cell Carcinoma